Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16401808 | 0.87 | NFKB1 (0.39) | NFKB1CES1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL95707 | 0.79 | CES2 (0.42) | CES1KDM4EHSD17B10NFE2L2CES2 | |
| SCHEMBL646513 | 0.79 | L3MBTL1 (0.44) | SLC22A12KDM4EHSD17B10LMNAGAA | |
| SCHEMBL28248522 | 0.79 | HSD11B1 (0.35) | SLC22A12HSD11B1PTGS2CES1KDM4E | |
| SCHEMBL909839 | 0.78 | SLC22A12 (0.44) | SLC22A12NFKB1HSD11B1PTGS2CES1 | |
| SCHEMBL7081521 | 0.73 | HSD11B1 (0.41) | HSD11B1CES1KDM4EGAAALDH1A1 | |
| SCHEMBL7705802 | 0.71 | CES2 (0.36) | CES1KDM4EHSD17B10CES2ALDH1A1 | |
| SCHEMBL3751767 | 0.71 | SLC22A12 (0.41) | SLC22A12NFKB1HSD11B1PTGS2CES1 | |
| SCHEMBL2047141 | 0.71 | EPHX2 (0.38) | SLC22A12CES1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL158739 | 0.71 | GABRA1 (0.40) | SLC22A12HSD11B1PTGS2CES1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | claimed |
| US-6150378-A | 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY | CEPHALON, INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| WO-2015008234-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| WO-2008028094-A1 | COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20060069037-A1 | Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors | CEPHALON, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| US-7001907-B2 | Peptide-containing α-ketoamide cysteine and serine protease inhibitors | CEPHAON, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-6703368-B2 | ENZYME INHIBITOR; FOR TREATMENT OF NERVOUS SYSTEM DISORDERS, STROKE, ALZHEIMER'S, PARKINSON'S AND HUNTINGTON'S DISEASES, AMYOTROPHY LATERAL SCLEROSIS, NEURONAL DAMAGE, CENTRAL NERVOUS SYSTEM INJURIES, ARTHRITIS, INFLAMMATION AND EPILEPSY | CEPHALON, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6288231-B1 | ENZYME INHIBITORS | CEPHALON, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6150378-A | 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY | CEPHALON, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0768301-A1 | N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | SLC22A12 3743/4885NFKB1 516/4885HSD11B1 1789/4885 |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | SLC22A12 568/4885NFKB1 3345/4885HSD11B1 173/4885 |
| US-20060069037-A1 | Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors | PREP, DNPEP, VIP | SLC22A12 2674/4885NFKB1 3083/4885HSD11B1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.